ArticleJournal of virology2026
Development of a vaccine based on mRNA assembly of PEDV virus-like particle.
Article in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Porcine epidemic diarrhea virus (PEDV) represents a highly contagious enteropathogenic coronavirus affecting swine. This virus elicits acute diarrhea in neonatal nursing piglets, with mortality approaching 100%, and, thus, imposes enormous economic burdens on the worldwide pork industry. Therefore, developing safe and effective vaccines remains a top priority for controlling PEDV. Here, we constructed a lipid-nanoparticle (LNP)-encapsulated messenger RNA (mRNA) vaccine. This vaccine encodes the four major structural proteins of PEDV: spike (S), membrane (M), envelope (E), and nucleocapsid (N), which self-assemble into virus-like particle (VLP). Compared with a PEDV S-only mRNA vaccine and a commercial PEDV/transmissible gastroenteritis virus (TGEV) bivalent inactivated vaccine in a mouse model, this VLP mRNA vaccine induced significantly higher levels of IgG, mucosal IgA, and neutralizing antibodies. It also enhanced the lymphocyte proliferation index and expanded the populations of T and B cells. Subsequent evaluations in sows showed that the VLP mRNA vaccine elicited robust PEDV-specific immune responses
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.